Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study,The Lancet Haematology

当前位置： X-MOL 学术 › Lancet Haematol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
The Lancet Haematology ( IF 15.4 ) Pub Date : 2024-06-14 , DOI: 10.1016/s2352-3026(24)00139-x
Yu Hu ₁ , Xiaofan Liu ₂ , Hu Zhou ₃ , Shujie Wang ₄ , Ruibin Huang ₅ , Yi Wang ₆ , Xin Du ₇ , Jing Sun ₈ , Zeping Zhou ₉ , Zhenyu Yan ₁₀ , Wenming Chen ₁₁ , Wei Wang ₁₂ , Qingchi Liu ₁₃ , Qingshu Zeng ₁₄ , Yuping Gong ₁₅ , Jie Yin ₁₆ , Xuliang Shen ₁₇ , Baodong Ye ₁₈ , Yun Chen ₁₉ , Yajing Xu ₂₀ , Huiping Sun ₂₁ , Yunfeng Cheng ₂₂ , Zhuogang Liu ₂₃ , Chunling Wang ₂₄ , Guolin Yuan ₂₅ , Xiaohui Zhang ₂₆ , Xin Li ₂₇ , Peng Cheng ₂₈ , Xinhong Guo ₂₉ , Zhongxing Jiang ₃₀ , Feng'e Yang ₃₁ , Linhua Yang ₃₂ , Chengwei Luo ₃₃ , Taiwu Xiao ₃₄ , Sisi Fu ₃₅ , Hongyan Yin ₃₅ , Xiaojun Guo ₃₅ , Qian Xu ₃₅ , Songhua Fan ₃₅ , Michael M Shi ₃₅ , Weiguo Su ₃₅ , Heng Mei ₁ , Renchi Yang ₂

Affiliation

Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Thrombosis and Haemostasis Diagnosis Treatment Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China.
Department of Hematology, Henan Cancer Hospital/The Affiliated Cancer Hospital of Zheng Zhou University, Zhengzhou, China.
Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Department of Hematology, Shaanxi Provincial People's Hospital, Xi'an, China.
Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Department of Hematology, Nanfang Hospital Southern Medical University, Guangzhou, China.
Department of Hematology, Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Department of Hematology, North China University of Science and Technology Affiliated Hospital, Tangshan, China.
Department of Hematology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China.
Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Department of Hematology, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Department of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Department of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China.
Department of Hematology, Heping Hospital Affiliated To Changzhi Medical College, Changzhi, China.
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Department of Hematology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Department of Hematology, Xiangya Hospital Central South University, Changsha, China.
Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Oncology, Jinshan Hospital of Fudan University, Shanghai, China.
Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
Department of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Department of Hematology, Xiangyang Central Hospital, Xiangyang, China.
Department of Hematology, Peking University People's Hospital, Beijing, China.
Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, China.
Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China.
Department of Hematology, Liaocheng People's Hospital, Liaocheng, China.
Medical Science, Clinical and Registration, HUTCHMED, Shanghai, China.

Sovleplenib, a novel spleen tyrosine kinase (SYK) inhibitor, showed promising safety and activity in patients with primary immune thrombocytopenia in a phase 1b/2 trial. We aimed to evaluate the efficacy and safety of sovleplenib in patients with chronic primary immune thrombocytopenia.

更新日期：2024-06-14

点击分享查看原文

点击收藏

阅读更多本刊新发论文